Cargando…

The Inhibition of Wnt Restrain KRAS(G12V)-Driven Metastasis in Non-Small-Cell Lung Cancer

The KRAS mutations have been an obstacle to identify therapeutic targets in cancer treatment. In this work, we clarified the distinct metastasis pattern of non-small-cell lung carcinoma (NSCLC) induced by KRAS(G12V)/KRAS(G12D) mutations and inhibited the KRAS(G12V) mediated metastasis by Wnt inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Pei-Shan, Huang, Ming-Hung, Kuo, Yuan-Yeh, Yang, James Chih-Hsin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226522/ https://www.ncbi.nlm.nih.gov/pubmed/32244355 http://dx.doi.org/10.3390/cancers12040837

Ejemplares similares

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility
por: Chen, Chih-Chieh, et al.
Publicado: (2020)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

Activated Kras(G12D) is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin
por: Rachagani, S, et al.
Publicado: (2011)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Depletion of VPS35 attenuates metastasis of hepatocellular carcinoma by restraining the Wnt/PCP signaling pathway
por: Liu, Yi, et al.
Publicado: (2020)

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
por: Tsai, Yihsuan S., et al.
Publicado: (2022)

Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
por: Huynh, Minh V., et al.
Publicado: (2022)

BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer
por: Ohnami, Shumpei, et al.
Publicado: (2021)

Reduced HRAS(G12V)-Driven Tumorigenesis of Cell Lines Expressing KRAS(C118S)
por: Huang, Lu, et al.
Publicado: (2015)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Arid1a restrains Kras-dependent changes in acinar cell identity
por: Livshits, Geulah, et al.
Publicado: (2018)

Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras(G12V) mice
por: Kumar, Gaurav, et al.
Publicado: (2021)

Fbxw7 Deletion Accelerates Kras(G12D)-Driven Pancreatic Tumorigenesis via Yap Accumulation()()()
por: Zhang, Qiang, et al.
Publicado: (2016)

Inactivation of Rbx1 E3 ligase suppresses Kras(G12D) ‐driven lung tumorigenesis
por: Li, Yanan, et al.
Publicado: (2023)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer
por: Weng, Ching-Chieh, et al.
Publicado: (2019)

An XIST-related small RNA regulates KRAS G-quadruplex formation beyond X-inactivation
por: Chang, Yuli C., et al.
Publicado: (2016)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Shape-Restrained Modeling of Protein–Small-Molecule Complexes with High Ambiguity Driven DOCKing
por: Koukos, Panagiotis I., et al.
Publicado: (2021)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Hyun, Soonsil, et al.
Publicado: (2021)

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS(G12D)-driven lung adenocarcinoma
por: Baltanás, Fernando C., et al.
Publicado: (2023)

Non-genetic adaptive resistance to KRAS(G12C) inhibition: EMT is not the only culprit
por: Ning, Wenjuan, et al.
Publicado: (2022)

Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer
por: Yaeger, Rona, et al.
Publicado: (2023)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
por: Araujo, Luiz Henrique, et al.
Publicado: (2021)

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
por: Wu, Markus Y., et al.
Publicado: (2021)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Efficacy of a Small-Molecule Inhibitor of Kras(G12D) in Immunocompetent Models of Pancreatic Cancer
por: Kemp, Samantha B., et al.
Publicado: (2023)

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
por: Lu, Kevin, et al.
Publicado: (2023)

Pentraxin 3 Inhibits Complement-driven Macrophage Activation to Restrain Granuloma Formation in Sarcoidosis
por: Gonçales, Relber A., et al.
Publicado: (2022)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway
por: Wei, Zhun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3i08mogd379sqjk6dgtkrh3mes